Cytokine Protocols
Preface

During the last 30 years there has been a growing interest in cytokines as biological molecules able to regulate the most diverse functions in living organisms, mainly at the level of cell–cell communication. Originally their definition was limited to the cells of the immune system (interleukins and lymphokines), but later that definition was extended to all cells, and their regulatory activity in such other processes as differentiation, apoptosis, angiogenesis, and wound healing has been now demonstrated. They comprise a group of small proteins (5–20 kDa) produced and released by cells in a tightly controlled fashion, active in the nano- or picomolar concentration range, and eliciting specific effects in neighboring cells; therefore, their action is said to be autocrine, paracrine, or juxtacrine. The latter property distinguishes them from hormones, which are produced by one tissue and are transported by the blood stream in order to act on a distant tissue. Chemokines are a subset of cytokines, but whether growth factors are included in the group is often a matter of discussion. The activity of several cytokines can be inhibited by other cytokines or by biological response modifiers; therefore, the latter are sometimes called “anti-cytokines.” The biological response of a particular cell is usually the result of the sum of all interactions with cytokines present at a certain time and in a certain sequence in time—the “cytokine network.” In order to understand the production and action of cytokines, experimental protocols at the DNA, RNA, protein, and (molecular) cell biological level are needed. This volume, Cytokine Protocols, in the Methods in Molecular Biology series describes a number of such protocols for specific cytokines, but most of them are broadly applicable and readily adaptable.

The first two chapters deal with DNA itself. Chapter 1 describes the large-scale generation and purification of plasmid DNA for use in such fields as gene therapy, DNA vaccination, transfection, and others, as well as the purity criteria that should be taken into account for such applications. Both the regulation of cytokine production and the expression of cytokine-induced protein synthesis are, at least in part, controlled by DNA–protein interactions, among which is the binding of transcription factors. One of the most direct and powerful methods, not only to demonstrate such interaction, but also to identify the interacting partners, is the gel mobility shift assay, as described in Chapter 2.

The next three chapters are concerned with phenomena at the RNA level. Again, both the induction of cytokine production and the sensitivity to their
action in terms of signal transduction, leading to the biological actions as a result of induced proteins, are in part the result of changes in RNA levels. Chapter 3 describes the generation of stable transfectants with antisense-RNA expression vectors, leading to cell lines with altered sensitivity for cytokines. This methodology allows the identification of signal transduction partners as well as that of alternative paths (leading to “cross-talk,” see also Chapter 18). Both the precise quantification and the localization of such RNAs are needed in order to obtain a complete picture. The use of a competitive RT-PCR method in order to quantify small amounts of mRNA is described in Chapter 4, whereas the localization of cytokine-related mRNAs in human tissue biopsies by in situ hybridization is described in Chapter 5.

The next five chapters deal with the isolation and characterization of cytokines, cytokine-related proteins, and their interactions. Cytokines, their cellular receptors, and the components of their signal transduction chain are all proteins that are present only at very low abundance. Their isolation and characterization, as well as methods for demonstrating their interactions, are described. Starting from large volumes of conditioned culture media followed by initial concentration steps, Chapter 6 describes the purification of chemokines until homogeneity by consecutive affinity and ion exchange chromatography followed by RP-HPLC. Complete characterization is achieved by SDS-PAGE, sequence analysis, and mass spectrometry, and confirmed by chemical synthesis and determination of biological activity (see Chapter 13 for assays of chemotaxis). Similar methodology is described in Chapter 7 for the isolation and characterization of cytokine receptors, including soluble receptors, i.e., the extracellular part of membrane receptors, which occur free in biological fluids (often urine) and are an excellent, more soluble substitute for studying interactions with the corresponding cytokine. Establishment of the biological activity of cytokines is initiated by the formation of a complex with their receptor; hence, great efforts are devoted to the elucidation of this structure down to the atomic level. Chapter 8 describes the common principles and an overview of experimental conditions used for crystallization of cytokine–receptor complexes. Protein–protein interactions are instrumental in the establishment of the biological effects, not only at the receptor level, but also between the partners in the signal transduction chain. One of the most direct means of measuring such biomolecular interactions both in terms of affinity ($K_d$, dissociation constant) and kinetically ($k_{on}$ and $k_{off}$) relies on the phenomenon of surface plasmon resonance. The principles and the practical elaboration of this method are the subjects of Chapter 9. The demonstration of such interactions within the signal transduction chain and the importance of posttranslational modifications are described in Chapter 10.
Taking into account the high specific biological activity of most cytokines, they are often best detected and quantified with a very sensitive bioassay and compared to international standard preparations. These functional tests are used initially to detect a cytokine activity; often a cytokine’s name refers to this original biological activity. Many cytokines were even first discovered in a functional test, which later proved to be a side activity of its true activity. Therefore, if cytokine concentrations are not expressed in “mass/volume,” but in “units/volume,” one should clearly describe the kind of assay that has been used and international standardization is an absolute requirement. Because it is not possible to cover all cytokine assays that are used at present, only the next four chapters are devoted to bioassays. The assays for antiviral activity (Chapter 11) and for cytotoxicity (Chapter 12) are rather similar, because, in fact, they both measure the number of cells remaining alive after impairing the viability of the cells. Three chemotaxis assays are described in Chapter 13: two in vitro assays, i.e., chemotaxis through micropores and chemotaxis under agarose, and one in vivo assay, i.e., the migration of $^{111}$In-labeled granulocytes (in rabbit). Finally, taking the hematopoietic growth factor granulocyte colony-stimulating factor as an example, Chapter 14 demonstrates that the data obtained from in vitro bioassays must necessarily be complemented or confirmed by in vivo measurements, since the eventual activity of a cytokine may definitely be subjected to secondary factors.

The last five chapters deal with (molecular) cell biological techniques. Chapter 15 describes the generation of stable transfectants that are able to interfere in a controlled fashion with the signal transduction path of a cytokine (in this case TNF-α). Taking into account the low molecular mass (and hence their rapid diffusion out of cells) of most cytokines as well as the extremely low level of their expression, the detection of cytokines at the single cell level is a major challenge. In Chapter 16, the immunohistochemical detection, and even double labeling, of cytokines in tissue sections is described, using either fluorescent or chromogenic substrates. Fixation and permeabilization, though preserving the cellular morphology and the antigenicity of intracellular proteins, seem to be crucial steps in the preparation of biological material. Optimized staining protocols for cytoplasmic, indirect immunofluorescent, or immunocytochemical detection on slides are described in Chapter 17; these are, however, not suited for the detection of antigens in the nucleus. Cytokines are not only pleiotropic signaling molecules, endowed with partially overlapping activities, in part they also use common or synergistically acting intracellular signal transduction compounds for establishing their final biological action. This leads to a phenomenon that is known as “cross-talk,” described in Chapter 18. Finally, the presence of noncytokine bioactive compounds, such as, for example, pros-
taglandins, may influence the outcome of cytokine stimulation by altering the ratio of producer or target cells, as described in Chapter 19.

These “cytokine protocols” are intended for use by researchers with knowledge of at least basic biochemistry, molecular biology, and cell culture techniques. It is also an absolute prerequisite to be familiar with biological safety regulations, particularly when working with human biological materials or with recombinant DNA harboring human sequences. Although each individual protocol is written for and applied on a certain cytokine, only minimal changes are required to adapt it to another. The chapters on assay systems may need more modification in order to be broadly applicable.

Marc De Ley
Contents

Preface ................................................................. v
Contributors .......................................................... xi

1 Large-Scale Generation of Plasmids that Express Type I Interferon
   Peter Härle and Daniel J. J. Carr ............................... 1

2 Identification of trans-Acting Factors by Electrophoretic Mobility Shift Assay
   Rebecca J. Chan, Min You, and Gen-Sheng Feng ............. 7

3 Modulation of the Interferon-γ Signal by Transfection of Cells with an Antisense-RNA Expressing Vector
   Leen Delrue and Marc De Ley .................................. 21

4 Competitive RT-PCR to Quantify Small Amounts of mRNA
   Gabriela Aust ...................................................... 31

5 In Situ Hybridization for Cytokines in Human Tissue Biopsies
   Emily Mathey, John Pollard, and Patricia Armati ............ 41

6 Purification, Identification, and Synthesis of Chemokines
   Patricia Menten, Anja Wuyts, and Jo Van Damme .......... 47

7 Receptor Isolation and Characterization: From Protein to Gene
   Daniela Novick and Menachem Rubinstein .................... 65

8 Crystallization of Cytokine–Receptor Complexes
   William J. Cook and Mark R. Walter .......................... 81

9 Biosensor Analysis of Receptor–Ligand Interactions
   Sheng-Jiun Wu and Irwin Chaiken .............................. 93

10 Analysis of SH2 Ligands and Identification of Sites of Interaction
    Manuel Baca ....................................................... 111

11 Assays for Antiviral Activity
    Anthony Meager ................................................... 121

12 Assays for Cytotoxicity
    Anthony Meager .................................................. 135
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Assays for Chemotaxis</td>
<td>Anja Wuyts, Patricia Menten, Nancy Van Osselaer, and Jo Van Damme</td>
<td>153</td>
</tr>
<tr>
<td>14</td>
<td>In Vitro and In Vivo Assays for High-Molecular-Weight Pegylated Muteins of Granulocyte Colony-Stimulating Factor</td>
<td>James F. Eliason, Nadine Tare, Sharon Bowen, Tomoaki Inoue, and Ikuro Horii</td>
<td>167</td>
</tr>
<tr>
<td>15</td>
<td>Development of a Mammalian Tet-On Expression Cell Line: Glucosylceramide Synthase Regulates TNF-(\alpha)-Induced Apoptosis</td>
<td>Yong-Yu Liu and Myles C. Cabot</td>
<td>177</td>
</tr>
<tr>
<td>16</td>
<td>Immunohistochemical Detection of Cytokines in Human Tissue Sections</td>
<td>Sandra Hulshof, Danny F. Dukers, Wim Vos, and Corline J. A. De Groot</td>
<td>193</td>
</tr>
<tr>
<td>17</td>
<td>Detection of Cytokine- and Chemokine-Expressing Cells at the Single Cell Level</td>
<td>Karin Loré and Jan Andersson</td>
<td>201</td>
</tr>
<tr>
<td>18</td>
<td>Detection of Cytokine Signal Transduction “Cross-Talk” in Leukocyte Activation</td>
<td>Howard R. Petty</td>
<td>219</td>
</tr>
<tr>
<td>19</td>
<td>Assay System for the Effect of Prostaglandin E(_2) in the Determination of Polarized Cytokine Production</td>
<td>Etsushi Kuroda and Uki Yamashita</td>
<td>229</td>
</tr>
<tr>
<td></td>
<td>Index</td>
<td></td>
<td>239</td>
</tr>
</tbody>
</table>
Contributors

Jan Andersson • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
Patricia Armati • School of Biological Sciences, University of Sydney, New South Wales, Australia
Gabriela Aust • Institute of Anatomy, University of Leipzig, Leipzig, Germany
Manuel Baca • The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
Sharon Bowen • Drug Discovery, Roche Research Center, F. Hoffmann-La Roche, Inc., Nutley, New Jersey, USA
Myles C. Cabot • John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, California, USA
Daniel J. J. Carr • Dean A. McGee Eye Institute, Department of Ophthalmology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
Irwin Chaiken • Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Rebecca J. Chan • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indianapolis, USA
William J. Cook • Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Corinne J. A. de Groot • Department of Pathology, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands
Marc de Ley • Laboratory of Biochemistry, Department of Chemistry, Katholieke Universiteit Leuven, Leuven, Belgium
Leen Delrue • Laboratory of Biochemistry, Department of Chemistry, Katholieke Universiteit Leuven, Leuven, Belgium
Danny F. Dukers • Department of Pathology, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands
James F. Eliason • Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
Gen-Sheng Feng • The Burnham Institute, La Jolla, California, USA
Peter Härle • Dean A. McGee Eye Institute, Department of Ophthalmology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA
IKUO HORII • Department of Toxicology, Nippon Roche Research Center, Kamakura, Japan
SANDRA HULSHOF • Department of Pathology, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands
TOMOAKI INOUE • Department of Toxicology, Nippon Roche Research Center, Kamakura, Japan
ETSUSHI KURODA • Department of Immunology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
YONG-YU LIU • John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, California, USA
KARIN LORÉ • Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
EMILY MATHEY • School of Biological Sciences, University of Sydney, New South Wales, Australia
ANTHONY MEAGER • Division of Immunobiology, The National Institute for Biological Standards and Control, South Mimms, Hertfordshire, UK
PATRICIA MENTEN • Laboratory of Molecular Immunology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
DANIELA NOVICK • Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel
HOWARD R. PETTY • Department of Biological Sciences, Wayne State University, Detroit, Michigan, USA
JOHN POLLARD • Department of Medicine, The University of Sydney, New South Wales, Australia
MENACHEM RUBINSTEIN • Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel
NADINE TARE • Drug Discovery, Roche Research Center, F. Hoffmann-La Roche Inc., Nutley, New Jersey, USA
JO VAN DAMME • Laboratory of Molecular Immunology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
NANCY VAN OSSELAER • Division of Pharmacology, Faculty of Medicine, University of Antwerp, Antwerpen, Belgium
WIM VOS • Department of Pathology, University Hospital, Vrije Universiteit, Amsterdam, The Netherlands
MARK R. WALTER • Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
SHENG-JIUN WU • Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
ANJA WUYTS • Laboratory of Molecular Immunology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium
Uki Yamashita • Department of Immunology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

Min You • VA Medical Center, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indianapolis, USA